The Role of Tumor-Associated Macrophages in Anti-PD-1/PD-L1 Immunotherapy for Lymphoma--Review.
10.19746/j.cnki.issn.1009-2137.2025.04.043
- Author:
Xing-Hui JIANG
1
;
Yi-Jian CHEN
2
Author Information
1. The First School of Clinical Medicine, Gannan Medical College，Ganzhou 341000, Jiangxi Province, China.
2. Department of Hematology, The First Affiliated Hospital of Gannan Medical College, Ganzhou 341000, Jiangxi Province, China.
- Publication Type:English Abstract
- Keywords:
lymphoma;
tumor-associated macrophage;
PD-1/PD-L1;
tumor microenvironment
- MeSH:
Humans;
Immunotherapy;
B7-H1 Antigen/immunology*;
Programmed Cell Death 1 Receptor/immunology*;
Tumor Microenvironment;
Lymphoma/immunology*;
Tumor-Associated Macrophages/immunology*
- From:
Journal of Experimental Hematology
2025;33(4):1217-1221
- CountryChina
- Language:Chinese
-
Abstract:
Lymphoma is a malignant tumor originating from lymphatic tissue, which can be roughly divided into two types: Hodgkin's lymphoma and non-Hodgkin's lymphoma. It has the characteristics of high recurrence rate, high mortality rate, and short survival time. Tumor cells in lymphoma form a tumor microenvironment (TME) that inhibits host anti-tumor immunity with surrounding immune cells, while tumor-associated macrophages (TAMs) are a key cell in TME. TAMs promote immune evasion of tumor cells in some ways by producing various cytokines and/or abnormal expression of immune checkpoint molecules. Programmed death receptor-1 (PD-1) and its ligand 1 (PD-L1) are important negative regulatory factors for immune cell activation. Recent studies have shown that anti-PD-1/PD-L1 therapy represents a new strategy for lymphoma immunotherapy. This article will focus on the role and expression of TAMs and PD-1/PD-L1 in lymphoma, and explore the efficacy of anti-PD-1/PD-L1 immunotherapy in different types of lymphoma.
